Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study-Reference-Cited by-同舟云学术

Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study

Published:2022-07-12 Issue:12 Volume:198 Page:1082-1093
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:en
Short-container-title:Strahlenther Onkol

Author:

Deng Rui,Liu Jinkun,Song Tongjun,Xu Tao,Li Yong,Duo Long,Xiang Longchao,Yu Xiongjie,Lei Jinhua,Cao Fengjun^ORCID

Funder

Guiding Project of Hubei Provincial Health and Health Commission

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology, Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s00066-022-01971-w.pdf

Reference32 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

2. Abdallah SM, Hirsh V (2018) Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Curr Oncol 25(Suppl 1):S9–S17. https://doi.org/10.3747/co.25.3732

3. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT (2017) The eighth edition lung cancer stage classification. Chest 151(1):193–203. https://doi.org/10.1016/j.chest.2016.10.010

4. Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J (2019) Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ 367:l5460. https://doi.org/10.1136/bmj.l5460

5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. https://doi.org/10.1016/s1470-2045(09)70364-x

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional local therapy before disease progression for EGFR-mutated advanced lung cancer: a systematic review and meta-analysis;Translational Lung Cancer Research;2024-03

3. PATIENTS WITH EGFR-MUTATED LUNG ADENOCARCINOMA AFTER PROGRESSION;ACTA MEDICA MEDITERR;2023